Cargando…

A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia

BACKGROUND: Patient affordability is an important nonclinical consideration for treatment access among patients with schizophrenia. OBJECTIVE: This study evaluated and measured out-of-pocket (OOP) costs for antipsychotics (APs) among Medicaid beneficiaries with schizophrenia. METHODS: Adults with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Dee, Pilon, Dominic, Morrison, Laura, Shah, Aditi, Lafeuille, Marie-Hélène, Lefebvre, Patrick, Benson, Carmela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491554/ https://www.ncbi.nlm.nih.gov/pubmed/37289413 http://dx.doi.org/10.1007/s40801-023-00376-0

Ejemplares similares

Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
por: Pilon, Dominic, et al.
Publicado: (2021)

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
por: Emond, Bruno, et al.
Publicado: (2018)

Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2018)

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
por: Pilon, Dominic, et al.
Publicado: (2017)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
por: El Khoury, Antoine C., et al.
Publicado: (2020)

Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
por: Lin, Dee, et al.
Publicado: (2021)

Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression
por: Olfson, Mark, et al.
Publicado: (2018)

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
por: Pilon, Dominic, et al.
Publicado: (2017)

Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With Schizophrenia
por: Li, Pengxiang, et al.
Publicado: (2023)

Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia
por: Basu, Anirban, et al.
Publicado: (2018)

Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies
por: Correll, Christoph U., et al.
Publicado: (2023)

Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Out-of-pocket health spending among Medicare beneficiaries: Which chronic diseases are most costly?
por: Fong, Joelle H.
Publicado: (2019)

Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
por: Zhdanava, Maryia, et al.
Publicado: (2022)

Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia
por: Basu, Anirban, et al.
Publicado: (2023)

Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation
por: Dickson, Matthew C., et al.
Publicado: (2022)

Prevalence and Medical Costs of Chronic Diseases Among Adult Medicaid Beneficiaries
por: Chapel, John M., et al.
Publicado: (2017)

Medicaid Highlights: 2003 Medicaid Versus Commercial Beneficiary Experience with Care
por: Lied, Terry R.
Publicado: (2005)

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)

Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
por: Dunn, Keith, et al.
Publicado: (2018)

Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents
por: Pilon, Dominic, et al.
Publicado: (2022)

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries
por: Lefebvre, Patrick, et al.
Publicado: (2012)

Medicaid Eligibility and Time to Re-incarceration Among Previously Incarcerated Subjects With Schizophrenia
por: Kozma, Chris, et al.
Publicado: (2016)

Improving Health-Based Payment for Medicaid Beneficiaries: CDPS
por: Kronick, Richard, et al.
Publicado: (2000)

Risk of Diabetes Mellitus Among Medicaid Beneficiaries in Hawaii
por: Li, Dongmei, et al.
Publicado: (2017)

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
por: Frois, Christian, et al.
Publicado: (2013)

Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey
por: Keenan, Alexander, et al.
Publicado: (2022)

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2013)

The Use Patterns of Medicaid Home and Community Based Services Among Medicare/Medicaid Beneficiaries With Dementia
por: Yan, Di, et al.
Publicado: (2021)

Chronic Disease Among Medicaid Beneficiaries Over 50: The Potential Impact of Medicaid Work Requirements
por: Sneed, Rodlescia, et al.
Publicado: (2021)

Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia
por: Noordsy, Douglas L, et al.
Publicado: (2010)

Follow-up Care among Medicaid Patients with Schizophrenia treated with Antipsychotics in the Inpatient Setting
por: Farr, Amanda M., et al.
Publicado: (2014)

Estimates of Insulin Out-of-Pocket Cap–Associated Prescription Satisfaction, Adherence, and Affordability Among Medicare Beneficiaries
por: Li, Minghui, et al.
Publicado: (2023)

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
por: Fu, Alex Z., et al.
Publicado: (2022)

Home-Care Use and Expenditures Among Medicaid Beneficiaries with AIDS
por: Sambamoorthi, Usha, et al.
Publicado: (1999)

Access of Rural AFDC Medicaid Beneficiaries to Mental Health Services
por: Lambert, David, et al.
Publicado: (1995)

End of Life Medicare and Medicaid Expenditures for Dually Eligible Beneficiaries
por: Liu, Korbin, et al.
Publicado: (2006)

End-of-Life Expenditures by Ohio Medicaid Beneficiaries Dying of Cancer
por: Koroukian, Siran M., et al.
Publicado: (2006)

Assessment of Medicaid Beneficiaries Included in Community Engagement Requirements in Kentucky
por: Venkataramani, Atheendar S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vsm2kq1gl1niomc4lg2qndth03